Maxalt

Rizatriptan, the active ingredient in Maxalt, is a selective serotonin 5‑HT1B/1D receptor agonist presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients who require rapid relief of headache and associated symptoms.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to healthcare providers across multiple regions.

Rizatriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the acute management of migraine.

- Migraine with aura: provides rapid relief of headache and associated symptoms. - Migraine without aura: reduces headache intensity and duration. - Acute migraine attacks in adults: enables patients to resume normal activities after an attack.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Tingling or numbness in the fingers or toes. - Warmth or flushing sensation. - Dizziness or light‑headedness. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Chest discomfort or tightness that may mimic cardiac ischemia. - Severe allergic reactions such as rash, swelling, or difficulty breathing. - Serotonin syndrome when combined with other serotonergic agents.

Before using Maxalt, consider the following safety measures.

- Cardiovascular disease: avoid if you have uncontrolled hypertension, coronary artery disease, or a history of stroke. - Medication overuse: limit use to avoid rebound headache. - Drug interactions: inform your prescriber of all concomitant medications, especially other triptans or serotonergic drugs. - Pregnancy and lactation: discuss risks with your healthcare provider; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Rizatriptan can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Ergot alkaloids: combined use may cause severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effect.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic agents: watch for serotonin syndrome symptoms. - CYP3A4 inhibitors (e.g., ketoconazole): may raise rizatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy.